Immunome (IMNM) Cash & Current Investments (2019 - 2026)

Immunome (IMNM) has 8 years of Cash & Current Investments data on file, last reported at $582.7 million in Q1 2026.

• Quarterly Cash & Current Investments rose 83.63% year-over-year to $582.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582.7 million (up 83.63% YoY) and the FY2025 annual result came in at $653.5 million, up 200.72% from the prior year.
• Cash & Current Investments retreated to $582.7 million in Q1 2026, from $653.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $653.5 million in Q4 2025 to a low of $20.3 million in Q4 2022.
• A 5-year average of $210.4 million and a median of $217.3 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 58.72% — and 2024, when it surged 624.52%.
• Tracing IMNM's Cash & Current Investments over 5 years: stood at $20.3 million in 2022, then surged by 579.73% to $138.1 million in 2023, then jumped by 57.3% to $217.3 million in 2024, then surged by 200.72% to $653.5 million in 2025, then decreased by 10.83% to $582.7 million in 2026.
• The last three Cash & Current Investments figures came in at $582.7 million (Q1 2026), $653.5 million (Q4 2025), and $272.6 million (Q3 2025), per Business Quant data.